Commerzbank Aktiengesellschaft FI lifted its position in Danaher Corporation (NYSE:DHR) by 55.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,952 shares of the conglomerate’s stock after acquiring an additional 50,373 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Danaher were worth $12,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of the company. BlackRock Inc. lifted its position in Danaher by 2,530.9% during the first quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock worth $3,247,398,000 after buying an additional 36,524,795 shares in the last quarter. Flossbach Von Storch AG lifted its position in Danaher by 44.7% during the second quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after buying an additional 1,785,810 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Danaher by 16,410.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP lifted its position in Danaher by 52.9% during the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after buying an additional 1,425,000 shares in the last quarter. Finally, Koch Industries Inc. lifted its position in Danaher by 29,127.3% during the second quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares in the last quarter. 76.32% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now directly owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of Danaher stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the sale, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at $25,173,715.68. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock valued at $25,218,813 over the last ninety days. Insiders own 12.20% of the company’s stock.
Shares of Danaher Corporation (NYSE:DHR) opened at $92.74 on Wednesday. Danaher Corporation has a 1 year low of $76.27 and a 1 year high of $94.82. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $64,566.07, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 2.21 and a beta of 1.02.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the previous year, the business earned $0.87 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. equities research analysts expect that Danaher Corporation will post 3.99 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s payout ratio is presently 16.52%.
A number of equities analysts recently commented on DHR shares. Morgan Stanley lifted their price objective on Danaher from $95.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 20th. Credit Suisse Group lifted their price objective on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research report on Thursday, October 5th. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 target price on shares of Danaher in a research report on Tuesday, September 26th. Finally, Robert W. Baird lifted their target price on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $93.31.
WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/06/danaher-corporation-dhr-shares-bought-by-commerzbank-aktiengesellschaft-fi.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.